

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3 (canceled)

Claim 4 (currently amended): A method for the treatment of rheumatoid arthritis in a patient in need of such treatment comprising administering to the patient an effective amount of a CD25 binding molecule; wherein the CD25 binding molecule comprises:

(a) ~~first domain at least one antigen binding site comprising at least one domain which comprises in sequence~~[[,]] the hypervariable regions CDR1, CDR2 and CDR3; the CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), the CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2) and the CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and

(b) a second domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', the CDR1' having the amino acid sequence Ser-Ala-Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), the CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO:5) and the CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6).

Claim 5 (previously presented): The method of claim 4, further comprising administering to the patient an effective amount of a further drug substance being effective in the treatment of rheumatoid arthritis.

Claims 6-7 (canceled)

Claim 8 (previously presented) A method according to claim 4 wherein the CD25 binding molecule is basiliximab.

Claims 9-12 (canceled)

Claim 13 (currently amended): The method of claim 4, wherein the first domain is part of an immunoglobulin heavy chain or fragment thereof and the second domain is part of an immunoglobulin light chain or fragment thereof.

Claim 14 (previously presented): The method of claim 4 wherein the CDC25 binding molecule is a chimeric anti-CD25 antibody.

Claim 15 (canceled)